Investor PresentationJuly 2020

The Path

Forward for

Psychedelic

Assisted

Psychotherapy

©2020 Core One Labs

2

Our Mission

To bring the world to life through psychedelics and

psychedelic enhanced psychotherapy.

2

©2020 Core One Labs

3

The Problem

Mental health conditions are on the rise.

Rapid Growth. Limited Treatments.

©2020 Core One Labs

4

Current treatments haven’t

changed in decades

and have proven

to be ineffective with

undesired side-effects

Addiction, Insomnia, Agitation, Loss of

Libido, Violent Impulses, Suicidal Impulses

75%

Non-adherence rates to anti-depressants

+2Point improvement on Hamilton

Depression Score (out of 52)

40-71%

Relapse rates

Side Effects

1. Star*D Study

©2020 Core One Labs

5

Source: Psilocybin with Psychological Support for Treatment Resistant

Depression, R. Carhart-Harris, The Lancet

Psychedelics: A Promising Solution

Evidence for Psychedelic Therapies

For depression

Extended relief from

depression >3months

For addiction

Addiction decreases after

psilocybin treatment

For general well-being

Sustained improvement in quality

of life and satisfaction

Pe

rce

nt

(%) o

fp

art

icip

an

ts

2 months after

methylphenidate

treatment

(control)

2 months

after

psi locybin

treatment

14 months

after

psi locybin

treatment

Pe

rce

nt

(%) o

f d

rin

kin

gd

ay

s

30

Weeks

1-4

Weeks

5-6

Weeks

9-12

Weeks

13-24

Weeks

25-36

First psilocybin treatment following

week 4 assessments

40

20

10

Severe

depression

Modera te

depression

Mi ld

depression

Before

treatment1

W eek

2

Weeks

3

Weeks

5

Weeks

3

Months

Source: Psilocybin-assisted treatment for alcohol dependence:

A proof- ofconcept study, M. Bogenshutz, Journal of Psychopharmacology

Source: Psilocybin-occasioned mystical-type experience in combination with

meditation [...] R. Griffiths, Journal of Psychopharmacology

The results from the clinical and academical studies on psychedelic-assisted psychotherapy are compelling

50

75

25

©2020 Core One Labs

6

Compared to other drugs, psychedelics have a

low harm profile

100=maximum

©2020 Core One Labs

77

*Sour1Source: Global Newswire, Reports and Data, May 2019

2Source: ”Botanical Supplements Market Size and Forecast, Hexa Research

September 20183Estimated at % of global cannabis market based on relative proportion of use.

Global Newswire, Reports and Data, May 2019.

**Source: US Substance Abuse and Mental Health Administration (SAMHSA)

Total Market Potential

$38BBotanical Supplements

Market

$10BIllustrative

Adult Use

Market

$16BAnxiety Disorder

&

Depression Treatment

Market 1

2

3

©2020 Core One Labs

8

Our Strategy

We are pursuing the development and

commercialization of rapid onset treatments capable

of improving health outcomes. Our first product is

CannaStrips which we will aim to use as a delivery

tool for cannabis and psychedelic treatments.

We will achieve this through R&D and Clinical Trials at

the University of British Columbia. We offer a fully

operational Clinic in British Columbia with 8 years of

operating history. The Clinic provides training and

education for medical professionals interested in

psychedelic assisted psychotherapy and psychedelic

integration psychotherapy.

Leveraging its existing SOPs, data driven research

sets and practitioner education modules, we will roll

out Clinics across Canada.8

©2020 Core One Labs

9

How Our Solution Works:

Psychedelic Assisted Psychotherapy

Using psychedelic molecules to catalyze the efficacy

of psychotherapy is showing great promise

Treatment Sessions

Approval of the treatment plan

First dosing session

Licensed psychotherapist, immediately

following the dosing session, provide

exploratory therapy.

Dosing sessions are typically

scheduled 2-3 days apart.

Integration Therapy

Psychotherapists will help your patient

integrate the experiences using

different clinical psychology techniques

Drive habit change and outlook/mindset

improvements.

On-Going Care

Typical treatment is 6 dosing sessions

with 3 integration sessions.

Patients will also have access to our

digital patient portal for on-going

support and education to help sustain

the effects of the KAP.

©2020 Core One Labs

10

Cognitive and Psychodynamic

Psychotherapists

Family Therapist

Adult Psychiatrist

Naturopathic Clinician

Indications for Clinical Treatment Rollout

Psychologist

Conduct comprehensive R&D campaigns

targeting the following indications:

Offer specialty therapy as a

complementary, follow-on service

Addiction

PTSD/Brain Injury

Treatment-Resistant Depression (TRD)

Aging/Dementia

Anxiety/Obsessive-Compulsive

Disorder (OCD)

©2020 Core One Labs

1111

CannaStrips™, a precisely dosed edible polymer delivery strip similar to a breath strip.

Current Delivery SystemEdible Polymer Sublingual Strips

Placed under the tongue CannaStrips™ deliver the active ingredient (functional mushrooms, Psilocybin THC, CBD, others) directly into circulation.

Avoids imprecise dosing and first-pass metabolism in the liver inherent with ingested products.

Core One Labs has control of all stages of production, distribution, transportation and delivery of CannaStrips™.

CannaStrips™ offer an effective dosage with no degradation of the liver. The result is a consistent, precise, and effective experience.

©2020 Core One Labs

12

Future TreatmentsPsychedelic-Enhanced Psychotherapy

Our therapy will use regulated dosages of psychedelic compounds like

ketamine and psilocybin in a safe, fully supervised setting. The treatment

will be used alongside psychotherapy.

These lower doses can promote better mental health by disrupting thought

patterns or loops that may be preventing progress.

The experience has been described as ”euphoric,” “calming,” and

“mystical.”

12

©2020 Core One Labs

13

As of Date to May 20, 2020

*estimated valuation

Comparables

ClinicsIntegrated

ModelFocus Molecule

Intellectual

Property

Valuation

(CAD)

Core One Labs Yes MultiPsilocybin,

Ketamine, THC

Delivery

Technology$45MM

Mydecine

Innovations GroupYes Clinic Psilocybin $140MM

MindMed No Drug Development 18-MC, LSD Phase 1, Phase 2 $145MM

Numinus Yes MultiPsilocybin,

Ketamine

Psilocybin

cultivation and

extraction license

$30MM

Cybin Yes Multi PsilocybinDelivery

Technology$60MM

Champignon

BrandsYes Multi Psilocybin+CBD Pre-clinical $150MM

Field Trip Yes MultiKetamine, FT-

104Ft-104 molecule $69MM

ATAI (Perception,

DemeRx)No

Drug

Development

Arketamine,

IbogaineUnknown $312MM

13

©2020 Core One Labs

14

1. Post-acquisition of Shacor and Rejuva

Capital Structure

Core One Labs 68,000,0001

Price $0.66

Market Cap $44,800,000

Cash $4,000,000

Assets $20,500,00

14

Thank YouCore One Labs Inc

1130 Pender Street West, Suite 820Vancouver, BC V6E 4A4 Canada

+1 (866) 347-5058